Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 315

1.

Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy.

Yamaguchi R, Janssen E, Perkins G, Ellisman M, Kitada S, Reed JC.

PLoS One. 2011;6(9):e24102. doi: 10.1371/journal.pone.0024102. Epub 2011 Sep 19.

2.

Clitocine induces apoptosis and enhances the lethality of ABT-737 in human colon cancer cells by disrupting the interaction of Mcl-1 and Bak.

Sun JG, Xiang J, Zeng XL, Li X, Wu P, Fung KP, Liu FY.

Cancer Lett. 2014 Dec 28;355(2):253-63. doi: 10.1016/j.canlet.2014.09.024. Epub 2014 Oct 7.

PMID:
25304383
3.
4.

Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition.

Tamaki H, Harashima N, Hiraki M, Arichi N, Nishimura N, Shiina H, Naora K, Harada M.

Oncotarget. 2014 Nov 30;5(22):11399-412.

5.

Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.

Hari Y, Harashima N, Tajima Y, Harada M.

Oncotarget. 2015 Dec 8;6(39):41902-15. doi: 10.18632/oncotarget.5881.

6.

Bcl-2 modulation to activate apoptosis in prostate cancer.

Bray K, Chen HY, Karp CM, May M, Ganesan S, Karantza-Wadsworth V, DiPaola RS, White E.

Mol Cancer Res. 2009 Sep;7(9):1487-96. doi: 10.1158/1541-7786.MCR-09-0166. Epub 2009 Sep 8.

7.

Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1.

Zhang C, Cai TY, Zhu H, Yang LQ, Jiang H, Dong XW, Hu YZ, Lin NM, He QJ, Yang B.

Mol Cancer Ther. 2011 Jul;10(7):1264-75. doi: 10.1158/1535-7163.MCT-10-1091. Epub 2011 May 12.

8.

Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.

Rahmani M, Aust MM, Hawkins E, Parker RE, Ross M, Kmieciak M, Reshko LB, Rizzo KA, Dumur CI, Ferreira-Gonzalez A, Grant S.

Haematologica. 2015 Dec;100(12):1553-63. doi: 10.3324/haematol.2015.130351. Epub 2015 Oct 9.

9.

The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.

Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB, Richardson A.

Clin Cancer Res. 2007 Dec 1;13(23):7191-8.

10.

Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.

Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J, Warner RB, Ng SC, Fesik SW, Elmore SW, Rosenberg SH, Tse C.

Cancer Res. 2007 Feb 1;67(3):1176-83.

11.

Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells.

Tsao T, Shi Y, Kornblau S, Lu H, Konoplev S, Antony A, Ruvolo V, Qiu YH, Zhang N, Coombes KR, Andreeff M, Kojima K, Konopleva M.

Ann Hematol. 2012 Dec;91(12):1861-70. doi: 10.1007/s00277-012-1537-8. Epub 2012 Aug 15.

12.

Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.

Simonin K, N'Diaye M, Lheureux S, Loussouarn C, Dutoit S, Briand M, Giffard F, Brotin E, Blanc-Fournier C, Poulain L.

Apoptosis. 2013 Apr;18(4):492-508. doi: 10.1007/s10495-012-0799-x.

PMID:
23344663
13.

Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma.

Fang H, Harned TM, Kalous O, Maldonado V, DeClerck YA, Reynolds CP.

Clin Cancer Res. 2011 Nov 15;17(22):7093-104. doi: 10.1158/1078-0432.CCR-11-0578. Epub 2011 Sep 20.

14.

Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.

Okumura K, Huang S, Sinicrope FA.

Clin Cancer Res. 2008 Dec 15;14(24):8132-42. doi: 10.1158/1078-0432.CCR-08-1665.

15.

Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.

He L, Torres-Lockhart K, Forster N, Ramakrishnan S, Greninger P, Garnett MJ, McDermott U, Rothenberg SM, Benes CH, Ellisen LW.

Cancer Discov. 2013 Mar;3(3):324-37. doi: 10.1158/2159-8290.CD-12-0417. Epub 2012 Dec 28.

16.

Rapid detection of an ABT-737-sensitive primed for death state in cells using microplate-based respirometry.

Clerc P, Carey GB, Mehrabian Z, Wei M, Hwang H, Girnun GD, Chen H, Martin SS, Polster BM.

PLoS One. 2012;7(8):e42487. doi: 10.1371/journal.pone.0042487. Epub 2012 Aug 3.

17.

Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.

Pan R, Ruvolo VR, Wei J, Konopleva M, Reed JC, Pellecchia M, Andreeff M, Ruvolo PP.

Blood. 2015 Jul 16;126(3):363-72. doi: 10.1182/blood-2014-10-604975. Epub 2015 Jun 4.

18.

The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.

Hikita H, Takehara T, Shimizu S, Kodama T, Shigekawa M, Iwase K, Hosui A, Miyagi T, Tatsumi T, Ishida H, Li W, Kanto T, Hiramatsu N, Hayashi N.

Hepatology. 2010 Oct;52(4):1310-21. doi: 10.1002/hep.23836.

PMID:
20799354
19.

Drp1 is dispensable for apoptotic cytochrome c release in primed MCF10A and fibroblast cells but affects Bcl-2 antagonist-induced respiratory changes.

Clerc P, Ge SX, Hwang H, Waddell J, Roelofs BA, Karbowski M, Sesaki H, Polster BM.

Br J Pharmacol. 2014 Apr;171(8):1988-99. doi: 10.1111/bph.12515.

20.

Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1.

Wu H, Schiff DS, Lin Y, Neboori HJ, Goyal S, Feng Z, Haffty BG.

Radiat Res. 2014 Dec;182(6):618-25. doi: 10.1667/RR13856.1.

Supplemental Content

Support Center